Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
Explore this paper's citation graph
Summary
It is highlighted that PCR-confirmed convalescent COVID-19 individuals develop SARS-CoV-2 RBD-specific IgG antibodies, which correlate strongly with theirneutralizing antibody titers, which can serve as a valuable surrogate measurement for neutralizing antibody responses.
- Type
- preprint
- Published
- 2020-09-01
- Cited by
- 29
- References
- 78
- Access
- Open access
- OpenAlex
- https://openalex.org/W3082794277
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:221510473
Keywords
Memory B cell, Antibody, Titer, Virology, Immunology
References
- Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute Chikungunya virus infection
- Buying Time—The Immune System Determinants of the Incubation Period to Respiratory Viruses
- Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination
- Role of Host Immune Response and Viral Load in the Differential Outcome of Pandemic H1N1 (2009) Influenza Virus Infection in Indian Patients
- Risk /Benefit Analysis
- Disappearance of antibodies to SARS-associated coronavirus after recovery.
- Influenza Virus-Specific Neutralizing IgM Antibodies Persist for a Lifetime
- Potent Neutralizing Serum Immunoglobulin A (IgA) in Human Immunodeficiency Virus Type 2-Exposed IgG-Seronegative Individuals
- Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity
- The neutralizing role of IgM during early Chikungunya virus infection
- Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus
- SARS-CoV-2 Vaccines: Status Report
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- Convalescent Plasma Therapy for COVID-19: State of the Art
- Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
- Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Cited by
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Whole blood derived covid convalescent plasma: A practical experience from India
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
- SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
- IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
- Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination
- Function Is More Reliable Than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination
- Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD
- Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
- Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study
- Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody
- A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021
- Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies
- Seroprevalence of anti SARS-CoV-2 IgG antibodies among adults in Jammu district, India: A community-based study
- Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
- Antibody tests for identification of current and past infection with SARS‐CoV‐2
- Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
- Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
- Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
- SARS-CoV-2 Serological Investigation of White-Tailed Deer in Northeastern Ohio
Related papers
- Two New Isotype-Specific Switching Activities Detected for Ig Class Switching1
- Ig isotype switching in B lymphocytes. A method for estimating isotype switch frequency in cloned B cell lymphomas.
- Mechanism and regulation of immunoglobulin isotype switching.
- Immunoglobulin class switch recombination machinery: progress and challenges.
- Mechanisms of isotype determination during immunoglobulin class switch recombination in human B-cells
- Immunoglobulin heavy-chain switching in pre-B leukaemias
- Models for the dynamics and order of immunoglobulin isotype switching
- CpG DNA redirects class‐switching towards "Th1‐like" Ig isotype production via TLR9 and MyD88